Peter Foley

12.0k citations
179 papers · 6.8k · 4 hit papers · h-index 43

Impact in

  • Dermatology top 0.05%
    • Dermatology and Skin Diseases
    • Skin Protection and Aging
    • Cutaneous lymphoproliferative disorders research
  • Immunology top 0.5%
    • Psoriasis: Treatment and Pathogenesis

Papers in

    • Psoriasis: Treatment and Pathogenesis 75
    • Dermatology and Skin Diseases 35
    • Skin Protection and Aging 11
    • Cutaneous lymphoproliferative disorders research 10

Peter Foley

164 papers receiving 6.6k citations

Peter Foley's Hit Papers

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial 2022 · 190 citations
1900+6+13Years since publication100200300400500

Peers

Peter Foley
Comparison fields: 5 of 153
  • Dermatology 2.7k
  • Immunology 2.8k
  • Epidemiology 1.7k
  • Rheumatology 564
  • Immunology and Allergy 185
Replace Gabriella Fabbrocini with:
Gabriella Fabbrocini Italy
Sergio Chimenti Italy
M.‐A. Richard France
Ketty Peris Italy
Pietro Quaglino Italy
Giovanni Damiani Italy
Vincent Ho Australia
Reva Bhushan United States
Alexander Stratigos Greece
Philippe Saïag France
Peter Foley relative to Gabriella Fabbrocini Italy Gabriella Fabbrocini's profile →
Citations per field
00.5×1.5×
Gabriella Fabbrocini · 1×
Citations per year

Countries citing papers authored by Peter Foley

Since Specialization
Citations

This map shows the geographic impact of Peter Foley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Foley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Foley more than expected).

Fields of papers citing papers by Peter Foley

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Foley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Foley. The network helps show where Peter Foley may publish in the future.

Co-authors

The 25 scholars most cited alongside Peter Foley, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter Foley Line = papers co-authored together Peter Foley links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 179 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial
Hit paper breakdown →
2017546
2
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
Hit paper breakdown →
2018470
3
Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: An international consensus
Hit paper breakdown →
2006464
4 2018297
5 1988292
6 1986229
7 2003207
8
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial
Hit paper breakdown →
2022190
9 2021182
10 2014167
11 2018139
12 2014129
13 1990126
14 2017107
15 2004107
16 202192
17 201888
18 201977
19 199372
20 200970

About Peter Foley

Peter Foley is a scholar working on Immunology, Dermatology, Epidemiology, Pathology and Forensic Medicine and Rheumatology, having authored 179 papers that have together received 6.8k indexed citations. Recurring topics across this work include Psoriasis: Treatment and Pathogenesis (75 papers), Dermatology and Skin Diseases (35 papers), Nonmelanoma Skin Cancer Studies (30 papers), Autoimmune Bullous Skin Diseases (14 papers), Asthma and respiratory diseases (11 papers), Skin Protection and Aging (11 papers), Pharmaceutical studies and practices (10 papers) and Cutaneous lymphoproliferative disorders research (10 papers). The work is most often cited by research in Dermatology (2.7k citations), Immunology (2.8k citations), Epidemiology (1.7k citations), Rheumatology (564 citations) and Immunology and Allergy (185 citations). Peter Foley has collaborated with scholars based in Australia, United States and Germany. Frequent co-authors include Kenneth B. Gordon, Robin Marks, Kristian Reich, Yaung‐Kaung Shen, Kim Papp, Michael Song, Graham G. Giles, Christopher Baker, April W. Armstrong and Yasmine Wasfi. Their work appears in journals such as Australasian Journal of Dermatology, British Journal of Dermatology, Journal of the American Academy of Dermatology, Journal of Dermatological Treatment and Journal of the European Academy of Dermatology and Venereology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact